Drug-Diagnostics Co-Development in Oncology
The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it...
Sparad:
| Huvudupphov: | |
|---|---|
| Materialtyp: | Online |
| Språk: | engelska |
| Utgiven: |
Frontiers Media SA
2021
|
| Ämnen: | |
| Länkar: | 18664 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|
| _version_ | 1869526307473195008 |
|---|---|
| author | Jan Trost Jorgensen |
| author_browse | Jan Trost Jorgensen |
| author_facet | Jan Trost Jorgensen |
| author_sort | Jan Trost Jorgensen |
| collection | Directory of Open Access Books |
| description | The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. This Research Topic on Drug-Diagnostic Co-Development in Oncology aims to provide you with an insight into some of the diverse activities that constitute this new research area. |
| format | Online |
| id | doab-20.500.12854ir-45512 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-455122024-03-31T13:09:45Z Drug-Diagnostics Co-Development in Oncology Jan Trost Jorgensen R5-920 RM1-950 RC254-282 Q1-390 IHC fish precision medicine NGS Drug-diagnostic co-development companion diagnostics oncology personalized medicine thema EDItEUR::M Medicine and Nursing The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. This Research Topic on Drug-Diagnostic Co-Development in Oncology aims to provide you with an insight into some of the diverse activities that constitute this new research area. 2021-02-11T11:49:13Z 2021-02-11T11:49:13Z 2016-03-10 08:14:32 2014 book 18664 16648714 9782889193325 https://directory.doabooks.org/handle/20.500.12854/45512 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/Drug-Diagnostics_Co-Development_in_Oncology/358#nogo http://journal.frontiersin.org/researchtopic/1313/drug-diagnostics-co-development-in-oncology Frontiers Media SA 10.3389/978-2-88919-332-5 10.3389/978-2-88919-332-5 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889193325 111 open access |
| spellingShingle | R5-920 RM1-950 RC254-282 Q1-390 IHC fish precision medicine NGS Drug-diagnostic co-development companion diagnostics oncology personalized medicine thema EDItEUR::M Medicine and Nursing Jan Trost Jorgensen Drug-Diagnostics Co-Development in Oncology |
| title | Drug-Diagnostics Co-Development in Oncology |
| title_full | Drug-Diagnostics Co-Development in Oncology |
| title_fullStr | Drug-Diagnostics Co-Development in Oncology |
| title_full_unstemmed | Drug-Diagnostics Co-Development in Oncology |
| title_short | Drug-Diagnostics Co-Development in Oncology |
| title_sort | drug diagnostics co development in oncology |
| topic | R5-920 RM1-950 RC254-282 Q1-390 IHC fish precision medicine NGS Drug-diagnostic co-development companion diagnostics oncology personalized medicine thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RM1-950 RC254-282 Q1-390 IHC fish precision medicine NGS Drug-diagnostic co-development companion diagnostics oncology personalized medicine thema EDItEUR::M Medicine and Nursing |
| url | 18664 |
| work_keys_str_mv | AT jantrostjorgensen drugdiagnosticscodevelopmentinoncology |